Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis
| Autor: | Carina Blomström Lundqvist, Sara Själander, Luis A. Garcia Rodriguez, Örjan Åkerborg, Guanyi Jin, Amrit Caleyachetty, Maria Huelsebeck, Kevin Bowrin, Bernhard Schaefer, Hovsep Mahdessian, Lucas Hofmeister, Lars-Åke Levin |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Sweden
Hälso- och sjukvårdsorganisation hälsopolitik och hälsoekonomi Pyridones DOAC Cost-Benefit Analysis Health Policy Administration Oral Anticoagulants Health Care Service and Management Health Policy and Services and Health Economy Dabigatran Stroke Rivaroxaban Atrial Fibrillation Humans Pyrazoles atrial fibrillation adherence oral anticoagulants cost-utility Aged |
| Zdroj: | Journal of Medical Economics. 25:1085-1091 |
| ISSN: | 1941-837X 1369-6998 |
| DOI: | 10.1080/13696998.2022.2116848 |
| Popis: | Aims A third of non-valvular atrial fibrillation (NVAF) patients are non-adherent to direct oral anticoagulants (DOACs). Estimates of the economic value of full adherence and the cost of two types of adherence improving interventions are important to healthcare planners and decision-makers. Methods A cost-utility analysis estimated the impact of non-adherence over a 20-year horizon, for a patient cohort with a mean age of 77 years, based on data from the Stockholm Healthcare database of NVAF patients with incident stroke between 2011 and 2018. Adherence was defined using a medication possession ratio (MPR) cut-off of 90%; primary outcomes were the number of ischemic strokes and associated incremental cost-utility ratio. Results Hypothetical comparisons between cohorts of 1,000 patients with varying non-adherence levels and full adherence (MPR >90%) predicted an additional number of strokes ranging from 117 (MPR = 81-90%) to 866 (MPR |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|